Publications [#322337] of Emily R. Derbyshire

Journal Articles

1. Kato, N; Comer, E; Sakata-Kato, T; Sharma, A; Sharma, M; Maetani, M; Bastien, J; Brancucci, NM; Bittker, JA; Corey, V; Clarke, D; Derbyshire, ER; Dornan, GL; Duffy, S; Eckley, S; Itoe, MA; Koolen, KMJ; Lewis, TA; Lui, PS; Lukens, AK; Lund, E; March, S; Meibalan, E; Meier, BC; McPhail, JA; Mitasev, B; Moss, EL; Sayes, M; Van Gessel, Y; Wawer, MJ; Yoshinaga, T; Zeeman, A-M; Avery, VM; Bhatia, SN; Burke, JE; Catteruccia, F; Clardy, JC; Clemons, PA; Dechering, KJ; Duvall, JR; Foley, MA; Gusovsky, F; Kocken, CHM; Marti, M; Morningstar, ML; Munoz, B; Neafsey, DE; Sharma, A; Winzeler, EA; Wirth, DF; Scherer, CA; Schreiber, SL, Diversity-oriented synthesis yields novel multistage antimalarial inhibitors., Nature, vol. 538 no. 7625 (October, 2016), pp. 344-349 [doi]
   (last updated on 2024/12/31)

   Abstract:
   Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds. Here we investigate whether antimalarial agents with novel mechanisms of action could be discovered using a diverse collection of synthetic compounds that have three-dimensional features reminiscent of natural products and are underrepresented in typical screening collections. We report the identification of such compounds with both previously reported and undescribed mechanisms of action, including a series of bicyclic azetidines that inhibit a new antimalarial target, phenylalanyl-tRNA synthetase. These molecules are curative in mice at a single, low dose and show activity against all parasite life stages in multiple in vivo efficacy models. Our findings identify bicyclic azetidines with the potential to both cure and prevent transmission of the disease as well as protect at-risk populations with a single oral dose, highlighting the strength of diversity-oriented synthesis in revealing promising therapeutic targets.